Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments

References

• HurNWChoiCBUhmWSBaeSCThe prevalence and trend of arthritis in Korea: results from Korea National health and nutrition examination surveysJ Korean Rheum Assoc2008151126
   Google Scholar
• McAlindonTEBannuruRRSullivanMCOARSI guidelines for the non-surgical management of knee osteoarthritisOsteoarthritis Cartilage20142236338824462672
   PubMed Web of Science ®Google Scholar
• DaiCStaffordRSAlexanderGCNational trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovationArch Intern Med200516517117715668363
   PubMed Web of Science ®Google Scholar
• Garcia RodríguezLAHernández-DíazSThe risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agentsArthritis Res200139810111178116
   PubMedGoogle Scholar
• CastellsagueJRiera-GuardiaNCalingaertBSafety of Non-Steroidal Anti-Inflammatory Drugs (SOS) ProjectIndividual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)Drug Saf201235121127114623137151
   PubMed Web of Science ®Google Scholar
• JüniPNarteyLReichenbachSSterchiRDieppePAEggerMRisk of cardiovascular events and rofecoxib: cumulative meta-analysisLancet20043642021202915582059
   PubMed Web of Science ®Google Scholar
• MukherjeeDNissenSETopolEJRisk of cardiovascular events associated with selective COX-2 inhibitorsJAMA200128695495911509060
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA)FDA Public Health Advisory: Safety of Vioxx Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106274.htmAccessed July 14, 2015
   Google Scholar
• European Medicines Agency (EAM) Working Group 2Benefit-risk methodology project Work package 2 report: Applicability of current tools and processes for regulatory benefit-risk assessment Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/10/WC500097750.pdfAccessed July 2, 2015
   Google Scholar
• FreyPBenefit–risk considerations in CDER: Development of a qualitative framework [Internet]Center for Drug Evaluation and Research (FDA) DIA Meeting2012 Available from: http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM317788.pdfAccessed July 2, 2015
   Google Scholar
• Mt-IsaSWangNHallgreenCEReview of methodologies for benefit and risk assessment of medication. IMI-PROTECT: London, 2013. Report No: 1 Available from: http://www.imi-protect.eu/documents/ShahruletalReviewofmethodologiesforbenefitandriskassessmentofmedicationMay2013.pdfAccessed July 2, 2015
   Google Scholar
• HaynesRBDevereauxPJGuyattGHPhysicians’ and patients’ choices in evidence based practiceBMJ2002324135012052789
   PubMed Web of Science ®Google Scholar
• FiebigDGHaasMHossainIStreetDJVineyRDecisions about Pap tests: what influences women and providers?Soc Sci Med2009681766177419339094
   PubMed Web of Science ®Google Scholar
• BryanSDolanPDiscrete choice experiments in health economics. For better or for worse?Eur J Health Econ20045319920215452734
   PubMedGoogle Scholar
• ArdenNKHauberABMohamedAFHow do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom?J Rheumatol2012391056106322422497
   PubMed Web of Science ®Google Scholar
• HauberABArdenNKMohamedAFA discrete-choice experiment of United Kingdom patients’ willingness to risk adverse events for improved function and pain control in osteoarthritisOsteoarthritis Cartilage20132128929723182815
   PubMed Web of Science ®Google Scholar
• AugustovskiFBeratarrecheaAIrazolaVPatient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experimentValue Health20131638539310.1016/j.jval.2012.11.00723538191
   PubMed Web of Science ®Google Scholar
• FraenkelLSuterLCunninghamCEHawkerGUnderstanding preferences for disease-modifying drugs in osteoarthritisArthritis Care Res (Hoboken)2014661186119224470354
   PubMed Web of Science ®Google Scholar
• MerkFDAArthritisDrugAdvisoryCommitteeMeetingBriefingDocument (Background Package) – Arcoxib (Etoricoxib), Protocol 007(2002)992015 Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4290b1-01-FDA.pdfAccessed September 9, 2015
   Google Scholar
• MerckFDAArthritisDrugAdvisoryCommitteeMeetingBriefingDocument (Background Package) – Arcoxia (Etoricoxib), Protocol 018(2007)992015 Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4290b1-01-FDA.pdf
   Google Scholar
• VillalbaMLMedical Review P3 – Rofecoxib, Protocol 029(1999)992015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021042_52_vioxx_medr_P3.pdf
   Google Scholar
• MerckFDAArthritisDrugAdvisoryCommitteeMeetingBriefingDocument (Background Package) – Arcoxia (Etoricoxib), Protocol 071(2005)992015 Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4290b1-02-Merck.pdf
   Google Scholar
• MerckFDA Arthritis Drug Advisory Committee Meeting Briefing Document (Background Package) – Arcoxia (Etoricoxib), Protocol 076(2007)992015 Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4290b1-02-Merck.pdf
   Google Scholar
• Merck FDA Arthritis Drug Advisory Committee Meeting Briefing Document (Background Package) – Arcoxia (Etoricoxib), Protocol 077(2007)992015 Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4290b1-02-Merck.pdf
   Google Scholar
• BinghamCO3rdSebbaAIRubinBREfficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studiesRheumatology (Oxford)200746349650716936327
   PubMed Web of Science ®Google Scholar
• BirbaraCRuoffGSheldonEEfficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studiesCurr Med Res Opin200622119921016393445
   PubMed Web of Science ®Google Scholar
• CannonGWCaldwellJRHoltPRofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study GroupArthritis Rheum200043597898710817549
   PubMed Web of Science ®Google Scholar
• CheungRChengTTDongYIncidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritisInt J Rheum Dis201013215115720536600
   PubMed Web of Science ®Google Scholar
• CollantesECurtisSPLeeKWA multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]BMC Fam Pract200231012033987
   PubMedGoogle Scholar
• CurtisSPBockowBFisherCEtoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]BMC Musculoskelet Disord200565816321158
   PubMed Web of Science ®Google Scholar
• DahlbergLEHolmeIHøyeKRingertzBA randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritisScand J Rheumatol200938213314319165648
   PubMed Web of Science ®Google Scholar
• DayRMorrisonBLuzaAA randomized trial of the efficacy and tolerability of the Cox-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofe-coxib/Ibuprofen Comparator Study GroupArch Intern Med2000160121781178710871971
   PubMedGoogle Scholar
• EmeryPZeidlerHKvienTKCelecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparisonLancet199935491962106211110609815
   PubMed Web of Science ®Google Scholar
• EssexMNBeharRO’ConnellMABrownPBEfficacy and tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritisInt J Gen Med2014722723524876792
   PubMedGoogle Scholar
• GebaGPWeaverALPolisABDixonMESchnitzerTJVioxx, Acetaminophen, Celecoxib Trial (VACT) GroupEfficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trialJAMA20022871647111754710
   PubMed Web of Science ®Google Scholar
• GottesdienerKSchnitzerTFisherCProtocol 007 Study GroupResults of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritisRheumatology (Oxford)20024191052106112209041
   PubMed Web of Science ®Google Scholar
• HawkeyCLaineLSimonTComparison of the effect of rofecoxib(a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study GroupArthritis Rheum200043237037710693877
   PubMed Web of Science ®Google Scholar
• LaineLHarperSSimonTA randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study GroupGastroenterology1999117477678310500058
   PubMed Web of Science ®Google Scholar
• LeungATMalmstromKGallacherAEEfficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trialCurr Med Res Opin2002182495812017209
   PubMed Web of Science ®Google Scholar
• MatsumotoAKMelianAMandelDREtoricoxib Rheumatoid Arthritis Study GroupA randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritisJ Rheumatol20022981623163012180720
   PubMed Web of Science ®Google Scholar
• CannonCPCurtisSPFitzGeraldGAMEDAL Steering CommitteeCardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonLancet200636895491771178117113426
   PubMed Web of Science ®Google Scholar
• ReginsterJYMalmstromKMehtaAEvaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritisAnn Rheum Dis200766794595117142385
   PubMed Web of Science ®Google Scholar
• SimonLSWeaverALGrahamDYAnti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trialJAMA1999282201921192810580457
   PubMed Web of Science ®Google Scholar
• BellamyNBuchananWWGoldsmithCHCampbellJStittLWValidation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or kneeJ Rheumatol19881512183318403068365
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGSpiegelhalterDJA re-evaluation of random-effects meta-analysisJ R Stat Soc Ser A Stat Soc2009172137159
   PubMed Web of Science ®Google Scholar
• HedayatASSloaneNJAStufkenJOrthogonal Arrays: Theory and ApplicationsNew YorkSpringer Verlag1999
   Google Scholar
• Reed JohnsonFLancsarEMarshallDConstructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task ForceValue Health20131631323337210
   PubMed Web of Science ®Google Scholar
• MorillasCFelicianoRCatalinaPFPatients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experimentPatient Prefer Adherence201591443145826508841
   PubMed Web of Science ®Google Scholar
• KaufTLMohamedAFHauberABFetzerDAhmadAPatients’ willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infectionPatient20125426527822775534
   PubMedGoogle Scholar
• FraenkelLBogardusSTJrConcatoJWittinkDRTreatment options in knee osteoarthritis: the patient’s perspectiveArch Intern Med20041641299130415226163
   PubMed Web of Science ®Google Scholar
• RatcliffeJBuxtonMMcGarryTSheldonRChancellorJPatients’ preferences for characteristics associated with treatments for osteoarthritisRheumatology (Oxford)20044333734514585925
   PubMed Web of Science ®Google Scholar
• VineyRLancsarELouviereJDiscrete choice experiments to measure consumer preference for health and healthcareExpert Rev Pharmacoecon Outcomes Res2002248996
   Google Scholar
• BridgesJFPHauberABMarshallDConjoint analysis applications I health: a checklist of the ISPOR good research practices for conjoint analysis task forceValue Health20111440341321669364
   PubMed Web of Science ®Google Scholar
• Report of the ISPOR Conjoint Analysis Good Research Practices Task ForceMethods for the Statistical Analysis of Discrete-Choice Experiments Available from: http://www.ispor.org/TaskForces/Conjoint-Analysis-Statistical-Analysis-forum-Milan%202015.pdfAccessed February 12, 2016
   Google Scholar
• ClarkMDDetermannDPetrouSMoroDde Bekker-GrobEWDiscrete choice experiments in health economics: a review of the literaturePharmacoeconomics201432988390225005924
   PubMed Web of Science ®Google Scholar